Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?Yair Lotan)
Urologic Oncology: Seminars and Original Investigations. 2014;32(1):47.e1-47.e8.Abstract
Objectives: To determine if the number of lymph nodes (LNs) removed is an independent predictor of biochemical recurrence (BCR) in patients without LN metastases undergoing radical prostatectomy (RP). Material and methods: Retrospective analysis of 7,310 patients treated at 7 centers with RP and pelvic LN dissection for clinically localized prostate cancer between 2000 and 2011. Patients with LN metastases (n = 398) and other reasons (stated later in the article) (n = 372) were excluded, which left 6,540 patients for the final analyses. Results: Overall, median biopsy and RP Gleason score were both 7; median prostate specific antigen level was 6. ng/ml (interquartile range [IQR]: 5); and median number of LNs removed was 6 (IQR: 8). A total of 3,698 (57%), 2,064 (32%), and 508 (8%) patients had ≥6, ≥10, and ≥20 LNs removed, respectively. Patients with more LNs removed were older, had a higher prostate specific antigen level, had higher clinical and pathologic T stage, and had higher RP Gleason score (all P<0.002). Within a median follow-up of 21 (IQR: 16) months, more LNs removed was associated with an increased risk of BCR (continuous: P = 0.021; categorical: P = 0.014). In multivariable analyses that adjusted for the effects of standard clinicopathologic factors, none of the nodal stratifications predicted BCR. Conclusions: The number of LNs did not have any prognostic significance in our contemporary cohort of patients with LN-negative prostate cancer. This suggests that the risk of missed clinically significant micrometastasis may be minimal in patients currently treated with RP and having a lower LN yield. © 2014 Elsevier Inc.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Alberto Briganti; Shahrokh F. Shariat; Felix K.-H. Chun; Georg C. Hutterer; Claus G. Roehrborn; Andrea Gallina; Patrizio Rigatti; Luc Valiquette; Francesco Montorsi; Pierre I. KarakiewiczBJU International. 2007;100(3):528-532.
Jose A. Karam; Robert S. Svatek; Pierre I. Karakiewicz; Andrea Gallina; Claus G. Roehrborn; Kevin M. Slawin; Shahrokh F. ShariatClinical Cancer Research. 2008;14(5):1418-1422.
Niccolo M. Passoni; Harun Fajkovic; Evanguelos Xylinas; Luis Kluth; Christian Seitz; Brian D. Robinson; Morgan Rouprêt; Felix K. Chun; Yair Lotan; Claus G. Roehrborn; et al.BJU International. 2014;114(4):503-510.
Appears in this Document